235 related articles for article (PubMed ID: 10211312)
21. Expression of p53, mdm2, p21/waf1 and bcl-2 proteins in thymomas.
Stefanaki K; Rontogianni D; Kouvidou CH; Bolioti S; Delides G; Pantelidaki A; Sotsiou F; Kanavaros P
Histopathology; 1997 Jun; 30(6):549-55. PubMed ID: 9205859
[TBL] [Abstract][Full Text] [Related]
22. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
Pfister C; Larue H; Moore L; Lacombe L; Veilleux C; Tetu B; Meyer F; Fradet Y
Int J Cancer; 2000 Jan; 89(1):100-4. PubMed ID: 10719738
[TBL] [Abstract][Full Text] [Related]
23. Human papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53, p21, mdm2, C-erbB2 and impact on survival.
Bahnassy AA; Zekri AR; Abdallah S; El-Shehaby AM; Sherif GM
Pathol Int; 2005 Feb; 55(2):53-62. PubMed ID: 15693850
[TBL] [Abstract][Full Text] [Related]
24. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression.
Osman I; Drobnjak M; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 Aug; 5(8):2082-8. PubMed ID: 10473090
[TBL] [Abstract][Full Text] [Related]
25. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma.
Jahnson S; Karlsson MG
Cancer; 2000 Aug; 89(3):619-29. PubMed ID: 10931462
[TBL] [Abstract][Full Text] [Related]
26. Expression of p53 and p21 proteins in oral squamous cell carcinoma: correlation with lymph node metastasis and response to chemoradiotherapy.
Tatemoto Y; Osaki T; Yoneda K; Yamamoto T; Ueta E; Kimura T
Pathol Res Pract; 1998; 194(12):821-30. PubMed ID: 9894247
[TBL] [Abstract][Full Text] [Related]
27. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.
Giannikaki E; Kouvidou C; Tzardi M; Stefanaki K; Koutsoubi K; Gregoriou M; Zois E; Kakolyris S; Mavroudi C; Delides G; Georgoulias V; Kanavaros P
Anticancer Res; 1997; 17(3C):2123-7. PubMed ID: 9216675
[TBL] [Abstract][Full Text] [Related]
28. p21WAF1/CIP1 expression is a marker of poor prognosis in oral squamous cell carcinoma.
Nemes JA; Nemes Z; Márton IJ
J Oral Pathol Med; 2005 May; 34(5):274-9. PubMed ID: 15817070
[TBL] [Abstract][Full Text] [Related]
29. MDM2/p53 co-expression in oral premalignant and malignant lesions: potential prognostic implications.
Agarwal S; Mathur M; Srivastava A; Ralhan R
Oral Oncol; 1999 Mar; 35(2):209-16. PubMed ID: 10435158
[TBL] [Abstract][Full Text] [Related]
30. Differential expressions of cyclin-dependent kinase inhibitors (p27 and p21) and their relation to p53 and Ki-67 in oral squamous tumorigenesis.
Choi HR; Tucker SA; Huang Z; Gillenwater AM; Luna MA; Batsakis JG; El-Naggar AK
Int J Oncol; 2003 Feb; 22(2):409-14. PubMed ID: 12527941
[TBL] [Abstract][Full Text] [Related]
31. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
32. p53, Cyclin D1, p21 (WAF1) and Ki-67 (MIB1) Expression at Invasive Tumour Fronts of Oral Squamous Cell Carcinomas and Development of Local Recurrence.
Sawair F; Hassona Y; Irwin C; Stephenson M; Hamilton P; Maxwell P; Gordon D; Leonard A; Napier S
Asian Pac J Cancer Prev; 2016; 17(3):1243-9. PubMed ID: 27039754
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas.
Valassiadou KE; Stefanaki K; Tzardi M; Datseris G; Georgoulias V; Melissas J; Tsiftsis DD; Delides G; Kanavaros P
Anticancer Res; 1997; 17(4A):2571-6. PubMed ID: 9252682
[TBL] [Abstract][Full Text] [Related]
34. MDM2 expression is associated with progress of disease and WAF1 expression in resected lung cancer.
Aikawa H; Sato M; Fujimura S; Takahashi H; Endo C; Sakurada A; Chen Y; Kondo T; Tanita T; Matsumura Y; Saito Y; Sagawa M
Int J Mol Med; 2000 Jun; 5(6):631-3. PubMed ID: 10812014
[TBL] [Abstract][Full Text] [Related]
35. Mdm2 and the p53 pathway in human pituitary adenomas.
Suliman M; Royds J; Cullen D; Timperley W; Powell T; Battersby R; Jones TH
Clin Endocrinol (Oxf); 2001 Mar; 54(3):317-25. PubMed ID: 11298083
[TBL] [Abstract][Full Text] [Related]
36. The unexplained survival of cells in oral cancer: what is the role of p53?
Whyte DA; Broton CE; Shillitoe EJ
J Oral Pathol Med; 2002 Mar; 31(3):125-33. PubMed ID: 11903817
[TBL] [Abstract][Full Text] [Related]
37. [Expression of proteins in p53 (p14ARF-mdm2-p53-p21WAF/CIP1) pathway and their significance in exocrine pancreatic carcinoma].
Yu GZ; Zhu MH; Ni CR; Li FM; Zheng JM; Gong ZJ
Zhonghua Bing Li Xue Za Zhi; 2004 Apr; 33(2):130-4. PubMed ID: 15132849
[TBL] [Abstract][Full Text] [Related]
38. Expression of p21WAF1/CIP1 is unrelated to p53 tumour suppressor gene status in oral squamous cell carcinomas.
Yook JI; Kim J
Oral Oncol; 1998 May; 34(3):198-203. PubMed ID: 9692054
[TBL] [Abstract][Full Text] [Related]
39. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
[TBL] [Abstract][Full Text] [Related]
40. Relationship between HPV16/18 E6 and 53, 21WAF1, MDM2, Ki67 and cyclin D1 expression in esophageal squamous cell carcinoma: comparative study by using tissue microarray technology.
Qi ZL; Huo X; Xu XJ; Zhang B; Du MG; Yang HW; Zheng LK; Li J; Shen ZY
Exp Oncol; 2006 Sep; 28(3):235-40. PubMed ID: 17080019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
